FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013710945> ?p ?o ?g. }

• W2013710945 endingPage "S256" @default.
• W2013710945 startingPage "S255" @default.
• W2013710945 abstract "Purpose/Objective: Radiation therapy is considered as a standard treatment after surgery for breast cancer in majority of all clinical cases. Adjuvant hormonotherapy with Tamoxifen is widely used in case of estrogeno-dependant post menopausic breast cancer. Experimental studies reported opposite results of the effects of Tamoxifen in combination with ionizing radiation. Recent clinical study confirmed the augmentation of lung fibrosis when these two agents are used in combination. Aromatase inhibitors, such as Letrozol (Femara®), seem to be superior than Tamoxifen in metastatic breast cancer disease with poorer side effects. An ongoing clinical randomised study is being comparing these two drugs in adjuvant setting. In this view, the goal of our study was to evaluate the benefit of the combination of radiation and Letrozol in a pre-clinical model. Materials/Methods: We used human mammary adenocarcinoma cell lines (MCF7–3 (1) and (2)) for all the experiments. MCF7–3 (1) and (2) are transfected cell lines with pHβ-Apr-1-neo vector and with the aromatase expression plasmid, pHβ-neo/aromatase cDNA, respectively. The cells were cultured in DCC and phenol red free medium. All irradiations were performed using a cobalt-60 source with ranging doses from 2 to 6 Gy. All cells were incubated with Letrozol and androstendione (100nM) during one week before the irradiation. To evaluate the effects of letrozol on aromatase activity, we used a radiometric aromatase assay (3H2O release assay). Cytotoxicities of letrozol (0.7μM–7nM) and radiotherapy used alone or in combination were evaluated using clonogenic, M.T.T., and cells numeration assays. In addition, cell cycle analysis using flow cytometry were performed to approach the mechanism of action of our experimental findings. Results: Treatment with Letrozol in MCF7–3 (2) shutted down the measured aromatase activity to the control cells level. Cells numeration assay showed an inhibition of 50 and 75% of the growth of the MCF7–3 (2) when Letrozol is used alone for more than 6 days at 0.7μM and 7nM, respectively. M.T.T. assay confirmed these first results. When radiation therapy was used alone, survival fraction decreased in a dose-dependant manner and survival curves were fitted using a linear-quadratic model. Survival fractions at 2 Gy (SF2) were 0.65 and 0.53 with radiation alone and radiation plus Letrozol, respectively (p=0.001). At 4 Gy, survival fractions were also statistically higher with radiation alone (0.56) than with radiation plus Letrozol (0.09, p=0.0001). Growth of MCF7–3 (2) was decrease by 76% (cells numeration) six days after radiotherapy (2 and 4 Gy) and Letrozol (0.7μM) treatment as compared to radiotherapy alone. This growth reduction of the MCF7–3 (2) cells was higher to 85% after twelve days of the same treatment combination. M.T.T. assay confirmed these results at 2 and 4 Gy in combination with Letrozol (0.7μM). After fifteen days of Letrozol (0.7μM) alone, cell cycle analyses showed a G1 arrest (77%) and a decrease of the S phase (13%) as compared to control cells, 63% and 27%, respectively. In combination treatment, as compared with radiation alone, we observed a decrease of the radio-induced G2 phase arrest (11% vs 15%), cell redistribution in the G1 phase (72% vs 62%), and a decrease of the S cell cycle phase (17% vs 23%). Conclusions: Letrozol is an active cytostatic or cytotoxic agent used alone in breast cancer transfected cell lines. In combination with radiation therapy, Letrozol has been proved to be a powerful radiosensitizer. These radiobiological results are the first pre-clinical findings of radiosensitization of Letrozol and will be further basis for adjuvant therapeutic combination in clinical settings." @default.
• W2013710945 created "2016-06-24" @default.
• W2013710945 creator A5014887650 @default.
• W2013710945 creator A5025960168 @default.
• W2013710945 creator A5026275112 @default.
• W2013710945 creator A5031202796 @default.
• W2013710945 creator A5060814256 @default.
• W2013710945 creator A5073379936 @default.
• W2013710945 creator A5081855440 @default.
• W2013710945 creator A5082011377 @default.
• W2013710945 creator A5089178811 @default.
• W2013710945 date "2003-10-01" @default.
• W2013710945 modified "2023-09-26" @default.
• W2013710945 title "Letrozole (Femara®) sensitises breast cancer cells to gamma irradiation" @default.
• W2013710945 doi "https://doi.org/10.1016/s0360-3016(03)01092-7" @default.
• W2013710945 hasPublicationYear "2003" @default.
• W2013710945 type Work @default.
• W2013710945 sameAs 2013710945 @default.
• W2013710945 citedByCount "2" @default.
• W2013710945 crossrefType "journal-article" @default.
• W2013710945 hasAuthorship W2013710945A5014887650 @default.
• W2013710945 hasAuthorship W2013710945A5025960168 @default.
• W2013710945 hasAuthorship W2013710945A5026275112 @default.
• W2013710945 hasAuthorship W2013710945A5031202796 @default.
• W2013710945 hasAuthorship W2013710945A5060814256 @default.
• W2013710945 hasAuthorship W2013710945A5073379936 @default.
• W2013710945 hasAuthorship W2013710945A5081855440 @default.
• W2013710945 hasAuthorship W2013710945A5082011377 @default.
• W2013710945 hasAuthorship W2013710945A5089178811 @default.
• W2013710945 hasBestOaLocation W20137109451 @default.
• W2013710945 hasConcept C117262875 @default.
• W2013710945 hasConcept C121608353 @default.
• W2013710945 hasConcept C126322002 @default.
• W2013710945 hasConcept C143998085 @default.
• W2013710945 hasConcept C2776166826 @default.
• W2013710945 hasConcept C2777176818 @default.
• W2013710945 hasConcept C2777863537 @default.
• W2013710945 hasConcept C2778812593 @default.
• W2013710945 hasConcept C502942594 @default.
• W2013710945 hasConcept C509974204 @default.
• W2013710945 hasConcept C530470458 @default.
• W2013710945 hasConcept C54355233 @default.
• W2013710945 hasConcept C71924100 @default.
• W2013710945 hasConcept C81885089 @default.
• W2013710945 hasConcept C86803240 @default.
• W2013710945 hasConceptScore W2013710945C117262875 @default.
• W2013710945 hasConceptScore W2013710945C121608353 @default.
• W2013710945 hasConceptScore W2013710945C126322002 @default.
• W2013710945 hasConceptScore W2013710945C143998085 @default.
• W2013710945 hasConceptScore W2013710945C2776166826 @default.
• W2013710945 hasConceptScore W2013710945C2777176818 @default.
• W2013710945 hasConceptScore W2013710945C2777863537 @default.
• W2013710945 hasConceptScore W2013710945C2778812593 @default.
• W2013710945 hasConceptScore W2013710945C502942594 @default.
• W2013710945 hasConceptScore W2013710945C509974204 @default.
• W2013710945 hasConceptScore W2013710945C530470458 @default.
• W2013710945 hasConceptScore W2013710945C54355233 @default.
• W2013710945 hasConceptScore W2013710945C71924100 @default.
• W2013710945 hasConceptScore W2013710945C81885089 @default.
• W2013710945 hasConceptScore W2013710945C86803240 @default.
• W2013710945 hasIssue "2" @default.
• W2013710945 hasLocation W20137109451 @default.
• W2013710945 hasOpenAccess W2013710945 @default.
• W2013710945 hasPrimaryLocation W20137109451 @default.
• W2013710945 hasRelatedWork W1491737910 @default.
• W2013710945 hasRelatedWork W1977513725 @default.
• W2013710945 hasRelatedWork W1996045572 @default.
• W2013710945 hasRelatedWork W1999183598 @default.
• W2013710945 hasRelatedWork W2028465294 @default.
• W2013710945 hasRelatedWork W2028501150 @default.
• W2013710945 hasRelatedWork W2040234260 @default.
• W2013710945 hasRelatedWork W2144224845 @default.
• W2013710945 hasRelatedWork W2161063011 @default.
• W2013710945 hasRelatedWork W2339773972 @default.
• W2013710945 hasVolume "57" @default.
• W2013710945 isParatext "false" @default.
• W2013710945 isRetracted "false" @default.
• W2013710945 magId "2013710945" @default.
• W2013710945 workType "article" @default.